iNFLAMMATION iMMUNOPATHOLOGY BIOTHERAPY

iNFLAMMATION
iMMUNOPATHOLOGY
BIOTHERAPY
U N I V E R S I T Y H O S P I TA L D E PA RT M E N T - D H U
The i2B Department has 32 médical and research teams working together
to improve the management of inflammatory and autoimmune diseases.
C O O R D I N AT O R S : P r o f . S e r g e A m s e l e m & P r o f . D a v i d K l a t z m a n n
T E N O N - S A I N T-A N TO I N E - A R M A N D -T R O U S S E AU - P I T I É-S A L P Ê T R I È R E - I N R A J O U Y- E N -J O S A S
CONTEXT
C
hronic inflammation, a condition
present in various diseases including
those with an immune component,
is an important cause of morbidity/
mortality in the developed world.
Recent advances on the pathophysiology of
autoinflammatory/autoimmune diseases have
led to a re-examination of their nosology.
It now appears that autoinflammatory and
autoimmune diseases do not represent two
distinct categories of disorders. Rather, they
form a disease continuum ranging from pure
autoinflammatory disorders to pure autoimmune
diseases, encompassing a large panel of
inflammatory diseases with some autoimmune
component, and vice versa. A wide range of
disorders fall into this disease category. These are
rare or common disorders, whose management
requires an integrated approach in which clinicians
from internal medicine or medical specialities and
research teams collaborate closely in translational
research programs.
RATIONALE
OBJECTIVE
The rationale of i2B is based on :
Our general objective is to study
and improve management of
inflammatory and autoimmune
diseases by integrating translational
information.
• The concept of autoinflammatory/autoimmune
disease continuum (AADC)
• The expected benefits of managing rare
disorders together with common diseases
• The importance of transition from pediatric to
adult healthcare departments
i2B disease CONTINUUM
AUTOINFLAMMATION
RARE MONOGENIC
AUTOINFLAMMATORY DISEASES
POLYGENIC
AUTOINFLAMMATORY
DISEASES
MIXED PATTERN DISEASES
CLASSIC POLYGENIC
AUTOIMMUNE DISEASES
(ORGAN SPECIFIC AND NONSPECIFIC)
RARE MONOGENIC
AUTOIMMUNE DISEASES
FMF, TRAPS, HIDS, CAPS, PAPA
Blau Syndrome
Crohn’s disease, ulcerative colitis
Degenerative diseases, e.g.osteoarthritis
Gout/pseudogout/other crystal arthropathies
Some categories of reactive arthritis and psoriasis/psoriatic arthritis
Congenital diseases with associated tissue inflammation
Non-antibody associated vasculitis including giant cell and Takayasu arteritis
Idiopathic uveitis
Erythma nodosum associated disease, including sarcoidosis
Ankylosing spondylitis
Reactive arthritis; psoriasis/psoriatic arthritis
Behcet’s syndrome
Uveitis (HLA-B27 associated)
Rheumatoid arthritis
Autoimmune uveitis (sympathetic ophthalmia)
Myasthenia gravis
Dermatomyositis, scleroderma
Goodpasture syndrome
ANCA-associated vasculitis
Type 1 diabetes
Sjogren’s syndrome
Systemic lupus erythematosus
Membranous nephropathy
ALPS
IPEX
Adapted from D. Mc Gonagle & M. McDermott PLoS Medicine August 2006
AUTOIMMUNITY
ALPS: Autoimmune Lymphoproliferative Syndrome, ANCA: Antineutrophil Cytoplasmic Antibodies, CAPS: Cryopyrin-Associated Periodic Syndrome; IPEX:
Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked, FMF: Familial Mediterranean Fever, HIDS: Hyperimmunoglobulinemia D with periodic
fever syndrome, HLA: Human Leukocyte Antigen, PAPA: Pyogenic Arthritis, Pyoderma gangrenosum, and severe cystic Acne, TRAPS: Tumour Necrosis
Factor Receptor– Associated Periodic fever Syndrome.
STRATEGY
I2B is a collegial network to strengthen the links between patient care, research, and teaching in the
field of autoimmune/autoinflammatory diseases. For this purpose, i2B projects are structured in four
complementary workpackages.
© INSERM/ Patrice Latron
1
Patient Care,
Cohorts, Deep
phenotyping &
Clinical trials
© INSERM/ Patrick Delapierre
2
Basic and
translational
research
Cross-analyse phenomic
data from cohorts of
patients with selected
inflammatory and
autoimmune diseases.
Identify new/common
molecular pathways in
several diseases and
validate pronostic and
diagnostic biomarkers.
© INSERM/ François Guenet
3
Translational
medicine and
biotherapy
© INSERM/ Etienne Begouen
4
Teaching and
dissemination
EXPECTED IMPACT
Develop and evaluate
biotherapies and novel
therapeutic targets.
Implement high-level teaching
and training activities for
healthcare professionals and
patients.
We aim to improve the classification, diagnosis, treatment and management of autoimmune/
autoinflammatory diseases so as to offer a better quality of life to patients. High-level teaching and
dissemination activities will spread knowledge and expertise in this cutting-edge field of medical science.
i2B TEAMS
Clinical Teams
Team Leader
Department
Hospital
F. Berenbaum
Rheumatology
Saint-Antoine
L. Baud
Department of Physiology
Tenon
J. Cabane
Internal Medecine
Saint-Antoine
P. Cacoub
Internal Medecine 2
Pitié-Salpêtrière
J. Cadranel
Department of Pneumology and Intensive Care Medecine
Tenon
A. Clement
Pediatric Pneumology
Trousseau
J. Cosnes
Gastroenterology and Nutrition
Saint-Antoine
B. Fautrel
Rheumatology
Pitié-Salpêtrière
G. Grateau
Internal Medecine
Tenon
P. Le Hoang
Ophthalmology
Pitié-Salpêtrière
S. Herson
Internal Medecine 1 and Integrated Gene Therapy Center
Pitié-Salpêtrière
M. Mayer
Neuropediatrics
Trousseau
P. Ronco
Nephrology and Dialysis
Tenon
E. Rondeau
Intensive care nephrology and Transplantation department
Tenon
T. Ulinski
Pediatric Nephrology
Trousseau
Clinical laboratory teams
Team Leader
Department
Hospital
S. Amselem
Molecular Genetics Unit
Trousseau
I. Brocheriou
Department of Pathology
Tenon
J. Capeau
Department of Biochemistry
Tenon
D. Klatzmann
Clinical Investigation Center for Biotherapies (CIC-BTi)
Pitié-Salpêtrière
D. Klatzmann
Biotherapy Unit
Pitié-Salpêtrière
G. Trugnan
Platform for Peptidomic, Metabolomic and drug Measurements (Mass
Spectrometry)
Saint-Antoine
Unit
Hospital
Research teams
Team Leader
S. Amselem
P. Aucouturier
O. Benveniste
Pathophysiology of Pediatric Genetic Diseases / UMRS 933 INSERM/
UPMC
Neuroimmunology / UMRS 938 INSERM / UPMC
Inflamed muscle and Innovative Targeted Therapies / U974 / UM76,
INSERM / UPMC
Trousseau
Saint-Antoine
Pitié-Salpêtrière
F. Berenbaum
Metabolism and age-related joint diseases / UMRS 938/INSERM / UPMC
Saint-Antoine
C. Chatziantoniou
From Kidney Phenotypic Alterations to Novel Diagnostic Markers and
Targets of Therapy of CKD / UMRS1155 INSERM / UPMC
Tenon
A. Clément
Pediatric Pneumology / UMRS 938 INSERM / UPMC
Trousseau
D. Klatzmann
P. Langella
P. Ronco
P. Seksik
A. Six
Immunology-Immunopathology-Immunotherapy / UMR 7211 - UMRS 959
UPMC / INSERM / CNRS
Commensal and Probiotics-Host Interactions Laboratory / UMR1319
Micalis INRA
From rare to common kidney diseases, remodeling and repair /
UMRS1155 INSERM / UPMC
Micro-organisms and Intestinal Physiopathology / ERL INSERM U1157 /
UMR7203 UPMC / INSERM / CNRS / ENS
Immunology-Immunopathology-Immunotherapy / UMR 7211 - UMRS 959
UPMC / INSERM / CNRS
Pitié-Salpêtrière
INRA
Tenon
Saint-Antoine
Pitié-Salpêtrière
i2B CONSORTIUM
Multidisciplinary and complementary
teams of excellence
Within i2B, 21 medical teams and 11 research
teams share and provide expertise in biological
and clinical aspects of inflammation, immunology,
genetics, microbiota and biotherapies. These
teams are located in four university hospitals,
(Pitié-Salpêtrière, Trousseau, Tenon and SaintAntoine) linked to Pierre and Marie Curie University
(UPMC), and one team is located at the Institut
National de la Recherche Agronomique (INRA).
The complementary expertise of i2B teams
covers the entire spectrum of the autoimmune/
autoinflammatory diseases. I2B has exclusive
clinical resources comprising more than 25
cohorts and one Clinical Investigation Center
specialized in biotherapies (CIC-BT). In addition,
i2B collaborates closely with 5 National Reference
Centers for Rare Diseases, the laboratory of
excellence Transimmunom and 14 patient groups.
15
Clinical Teams
(adult and pediatric)
6
Clinical Laboratory
Research Teams
Internal medecine,
rheumatology, gastroenterology,
nephrology, ophthalmology,
pneumology, neurology
> 25 cohorts
Labex
Transimmunom
3 academic laboratories and
3 biotech companies
(INSERM, CNRS, INRA,
UPMC)
H O S P I TA L U N I V E R S I T Y D E PA•RT
MENT - DHU
Autoimmune/Inflammatory
Pitié–Salpêtrière, Saint-Antoine,
Tenon and Trousseau hospitals
1
Research Teams
iNFLAMMATION
5
iMMUNOPATHOLOGY
National Reference
BIOTHERAPY
Centers for Rare Diseases
1
Clinical Investigation
Center in Biotherapy
11
Systemic Rare Diseases
• Pediatric Lung Diseases
• Secondary Amyloidosis and
Familial Mediterranean Fever
• Rare Hereditary Renal Diseases
• Neuromuscular Diseases
14
Patient groups
ANDAR, AFPric, AFA, AFLAR, AFS,
AFFMF, Association contre l’amylose,
AFM, Respirer C’est Grandir, FNAIR,
AIRG, Fondation du Rein, RENIF, VLM
ANDAR : Association Nationale de Défense Contre l’Arthrite Rhumatoide, AFPric : Association Française des Polyarthritiques, AFLAR, AFS : Association
Française des Spondylarthritiques, AFM : Association Française Contre les Myopathies, AFFMF : Association Française de la Fièvre Méditéranéenne Familiale,
FNAIR : Fédération Nationale Des Insuffisants Rénaux, RENIF : Réseaux de Néphrologie d’Ile de France, AFA : Association François Aupetit; VLM : Vaincre la
Mucoviscidose.
CO O RD INATOR S
Prof. Serge Amselem
Hôpital Armand Trousseau
Service de génétique
26 avenue du Dr Arnold Netter
75012 Paris
Prof. David Klatzmann
Hôpital Pitié-Salpêtrière
CIC Biothérapie
47-83 boulevard de l’hôpital
75013 Paris
[email protected]
Tél. 01 44 73 52 95
[email protected]
Tél. 01 42 17 74 61
PARIS
Tenon
Saint-Antoine
Armand-Trousseau
Pitié-Salpêtrière
INRA
Jouy en Josas
PA R T NE R S
CON TACT
Dr Caroline Aheng - Project Manager
Mail : caroline. [email protected] Tél. : 01 42 17 74 67
iNFLAMMATION
iMMUNOPATHOLOGY
BIOTHERAPY
U N I V E R S I T Y H O S P I TA L D E PA RT M E N T - D H U
http://www.dhu-i2b.fr
Création : i-breed.com Crédits photo © INSERM/ Banque Serimidis
PU BL IC